CY1114418T1 - Αλατα προσθηκης αμινων που περιεχουν υδροξυλικες ή/και καρβοξυλικες ομαδες με παραγωγα αμινονικοτινικου οξεως ως αναστολεις της dhodh - Google Patents

Αλατα προσθηκης αμινων που περιεχουν υδροξυλικες ή/και καρβοξυλικες ομαδες με παραγωγα αμινονικοτινικου οξεως ως αναστολεις της dhodh

Info

Publication number
CY1114418T1
CY1114418T1 CY20131100818T CY131100818T CY1114418T1 CY 1114418 T1 CY1114418 T1 CY 1114418T1 CY 20131100818 T CY20131100818 T CY 20131100818T CY 131100818 T CY131100818 T CY 131100818T CY 1114418 T1 CY1114418 T1 CY 1114418T1
Authority
CY
Cyprus
Prior art keywords
groups
aminicotinic
dodh
suspensions
carboxylic groups
Prior art date
Application number
CY20131100818T
Other languages
English (en)
Inventor
Garcia Juan Bautista Perez
Original Assignee
Almirall, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall, S.A. filed Critical Almirall, S.A.
Publication of CY1114418T1 publication Critical patent/CY1114418T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά καινοτόμα, υδατοδιαλυτά φαρμακευτικά αποδεκτά κρυσταλλικά άλατα προσθήκης (i) μιας αμίνης που περιέχει μία ή περισσότερες υδροξυλικές ή/και καρβοξυλικές ομάδες με (ii) παράγωγα αμινονικοτινικού οξέως του χημικού τύπου (Ι), όπου τα Ra, Rb, Rc και Rd αντιπροσωπεύουν ανεξάρτητα το καθένα ομάδες που επιλέγονται από άτομα υδρογόνου, άτομα αλογόνου, αλκυλομάδες C1-4 οι οποίες μπορεί να είναι προαιρετικά υποκατεστημένες με 1, 2 ή 3 υποκατάστατα που επιλέγονται από άτομα αλογόνου και υδροξυομάδες, και αλκοξυομάδες C1-4 οι οποίες μπορεί να είναι προαιρετικά υποκατεστημένες με 1, 2 ή 3 υποκατάστατα που επιλέγονται από άτομα αλογόνου και υδροξυομάδες, καθώς και τα φαρμακευτικά αποδεκτά διαλυτώματα αυτών.
CY20131100818T 2009-03-13 2013-09-18 Αλατα προσθηκης αμινων που περιεχουν υδροξυλικες ή/και καρβοξυλικες ομαδες με παραγωγα αμινονικοτινικου οξεως ως αναστολεις της dhodh CY1114418T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382031A EP2228367A1 (en) 2009-03-13 2009-03-13 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP10708932.8A EP2406225B1 (en) 2009-03-13 2010-03-11 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors

Publications (1)

Publication Number Publication Date
CY1114418T1 true CY1114418T1 (el) 2016-08-31

Family

ID=40677683

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100818T CY1114418T1 (el) 2009-03-13 2013-09-18 Αλατα προσθηκης αμινων που περιεχουν υδροξυλικες ή/και καρβοξυλικες ομαδες με παραγωγα αμινονικοτινικου οξεως ως αναστολεις της dhodh

Country Status (35)

Country Link
US (1) US20120014918A1 (el)
EP (2) EP2228367A1 (el)
JP (1) JP5674685B2 (el)
KR (1) KR101674699B1 (el)
CN (1) CN102348689B (el)
AR (1) AR075738A1 (el)
AU (1) AU2010223528B2 (el)
BR (1) BRPI1006766B8 (el)
CA (1) CA2754804C (el)
CL (1) CL2011002216A1 (el)
CO (1) CO6420337A2 (el)
CY (1) CY1114418T1 (el)
DK (1) DK2406225T3 (el)
EA (1) EA022350B1 (el)
EC (1) ECSP11011365A (el)
ES (1) ES2428746T3 (el)
HK (1) HK1162487A1 (el)
HR (1) HRP20130851T1 (el)
IL (1) IL214519A (el)
ME (1) ME01564B (el)
MX (1) MX2011009146A (el)
MY (1) MY155140A (el)
NZ (1) NZ594493A (el)
PE (1) PE20120171A1 (el)
PL (1) PL2406225T3 (el)
PT (1) PT2406225E (el)
RS (1) RS52949B (el)
SG (1) SG173823A1 (el)
SI (1) SI2406225T1 (el)
SM (1) SMT201300104B (el)
TW (1) TWI428127B (el)
UA (1) UA105786C2 (el)
UY (1) UY32467A (el)
WO (1) WO2010102826A1 (el)
ZA (1) ZA201105744B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
EP2594271A1 (en) * 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
KR101251851B1 (ko) 2011-11-30 2013-04-10 현대자동차주식회사 Ｉｓｇ 시스템 및 이의 제어방법
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2983649A1 (en) * 2013-04-12 2016-02-17 Actavis Group PCT ehf Pemetrexed formulation
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
CN112969699A (zh) 2018-10-09 2021-06-15 亚狮康私人有限公司 瓦利替尼的丙二酸盐
MX2021007536A (es) * 2018-12-21 2021-09-23 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.
US20230390276A1 (en) * 2020-10-15 2023-12-07 Aslan Pharmaceuticals Pte. Ltd. Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
PL352430A1 (en) * 1999-06-10 2003-08-25 Warner Lambert Co Method of inhibiting agreggation of amyloid proteins and visualising amyloid deposits
EP1381356B1 (en) 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JP2004099586A (ja) * 2002-05-21 2004-04-02 Sumitomo Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害剤
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
US20070219224A1 (en) 2004-05-21 2007-09-20 Uab Research Foundation, The Compositions and Methods Relating to Pyrimidine Synthesis Inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
KR20070065888A (ko) 2004-10-19 2007-06-25 아벤티스 파마슈티칼스 인크. 염증성 장질환을 치료하기 위한(ｚ)-2-시아노-3-하이드록시-부트-2-엔산-(4'-트리플루오로메틸페닐)-아미드의 용도
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
ZA201105744B (en) 2012-04-25
JP5674685B2 (ja) 2015-02-25
WO2010102826A1 (en) 2010-09-16
UY32467A (es) 2010-05-31
MX2011009146A (es) 2011-09-15
IL214519A0 (en) 2011-09-27
EP2406225B1 (en) 2013-06-26
CO6420337A2 (es) 2012-04-16
US20120014918A1 (en) 2012-01-19
ME01564B (me) 2014-09-20
AU2010223528A1 (en) 2011-08-25
AU2010223528B2 (en) 2017-02-16
RS52949B (en) 2014-02-28
HRP20130851T1 (hr) 2013-10-25
JP2012520252A (ja) 2012-09-06
TW201034669A (en) 2010-10-01
KR101674699B1 (ko) 2016-11-09
KR20110126694A (ko) 2011-11-23
CL2011002216A1 (es) 2012-03-09
AR075738A1 (es) 2011-04-20
EP2406225A1 (en) 2012-01-18
EP2228367A1 (en) 2010-09-15
EA201101297A1 (ru) 2012-04-30
ES2428746T3 (es) 2013-11-11
CA2754804A1 (en) 2010-09-16
PE20120171A1 (es) 2012-03-01
EA022350B1 (ru) 2015-12-30
PL2406225T3 (pl) 2013-12-31
SI2406225T1 (sl) 2013-10-30
CN102348689A (zh) 2012-02-08
NZ594493A (en) 2013-11-29
CA2754804C (en) 2018-07-24
IL214519A (en) 2015-03-31
BRPI1006766B1 (pt) 2021-03-23
SMT201300104B (it) 2013-11-08
DK2406225T3 (da) 2013-09-30
MY155140A (en) 2015-09-15
UA105786C2 (uk) 2014-06-25
TWI428127B (zh) 2014-03-01
HK1162487A1 (en) 2012-08-31
CN102348689B (zh) 2014-05-14
ECSP11011365A (es) 2011-10-31
SG173823A1 (en) 2011-09-29
BRPI1006766B8 (pt) 2021-05-25
PT2406225E (pt) 2013-09-19

Similar Documents

Publication Publication Date Title
CY1114418T1 (el) Αλατα προσθηκης αμινων που περιεχουν υδροξυλικες ή/και καρβοξυλικες ομαδες με παραγωγα αμινονικοτινικου οξεως ως αναστολεις της dhodh
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1121599T1 (el) Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
CY1114452T1 (el) Ενωσεις πυρρολιου
CY1119422T1 (el) Παραγωγα μπετουλινης
CY1117157T1 (el) Υποκατεστημενο παραγωγο ισοκινολινης
CY1114141T1 (el) Ενωσεις που εχουν ανταγωνιστικη του crth2 δραστηριοτητα
CY1119423T1 (el) Παραγωγο κυκλοαλκυλ-υποκατεστημενης ιμιδαζολης
CY1123670T1 (el) Κρυσταλλικο παραγωγο 6,7-ακορεστης-7-καρβαμοϋλ μορφινανης, και μεθοδος για την παραγωγη αυτου
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
EA201290260A1 (ru) Бензимидазол-имидазольные производные
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1109821T1 (el) Ενωσεις πιπεραζινης με ζιζανιοκτονα δραση
CY1113764T1 (el) Βενζοϊκου οξεος (1-φαινυλ-2-πυριδιν-4-υλ) αιθυλ εστερες ως αναστολεις φωσφοδιεστερασης
CY1115643T1 (el) Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
EA201170096A1 (ru) Замещенные производные пиримидона
CY1115469T1 (el) Παραγωγα βενζοφουρανιου
MX346746B (es) Compuestos de anillo indeno-fusionados.
UA109525C2 (xx) Алкіламідна сполука і її застосування